{"id":3386,"date":"2026-03-31T20:06:05","date_gmt":"2026-03-31T20:06:05","guid":{"rendered":"https:\/\/99puritypeptides.com\/?p=3386"},"modified":"2026-03-31T21:37:24","modified_gmt":"2026-03-31T21:37:24","slug":"tesamorelin-visceral-fat-research","status":"publish","type":"post","link":"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-research\/","title":{"rendered":"Tesamorelina y la Grasa Visceral: Lo que la Investigaci\u00f3n Muestra"},"content":{"rendered":"\n[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/3d-medical-background-with-virus-cells-dna-strand-scaled.jpg&#8221; parallax=&#8221;on&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; min_height=&#8221;500px&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#08171a&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Tesamorelin and Visceral Fat: What the Research Shows&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;81%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;Introduction&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;18px&#8221; width=&#8221;81%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; global_colors_info=&#8221;{}&#8221;]<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\">Not all fat is created equal. While subcutaneous fat \u2014 the kind you can pinch beneath the skin \u2014 is largely cosmetic, visceral fat is a different matter entirely. Stored deep in the abdominal cavity and wrapped around the organs, visceral adipose tissue (VAT) is metabolically active, pro-inflammatory, and directly associated with cardiovascular disease, insulin resistance, and metabolic syndrome.<o:p><\/o:p><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\">Tesamorelin (a synthetic analog of growth hormone-releasing hormone, or GHRH) has emerged as one of the most targeted and well-studied peptide compounds in visceral fat research. Unlike general weight-loss agents, tesamorelin acts specifically on the GH\/IGF-1 axis to selectively mobilize visceral fat \u2014 without meaningfully altering subcutaneous fat or overall body weight in most research models.<o:p><\/o:p><\/p>[\/et_pb_text][et_pb_heading title=&#8221;Here\u2019s what the current research shows.&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;81%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;What Is Tesamorelin and How Does It Work?&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;18px&#8221; width=&#8221;81%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; global_colors_info=&#8221;{}&#8221;]<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\">Tesamorelin is a 44-amino-acid synthetic peptide that mirrors the full sequence of human GHRH, with a trans-3-hexenoic acid modification at the N-terminus. This lipophilic addition enhances binding affinity at the GHRH receptor and provides resistance to enzymatic degradation \u2014 giving it a more durable pharmacokinetic profile than native GHRH.<o:p><\/o:p><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\">The mechanism operates through the pituitary gland. Tesamorelin binds to GHRH receptors on somatotroph cells, stimulating pulsatile, endogenous growth hormone (GH) secretion. That GH rise subsequently elevates insulin-like growth factor-1 (IGF-1), which plays the key downstream role in fat metabolism and body composition changes.<o:p><\/o:p><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\">Critically, this is a physiologic stimulation \u2014 not an exogenous GH injection. The pituitary\u2019s natural negative feedback mechanisms remain intact, which is one reason tesamorelin\u2019s effects appear selective to visceral fat rather than producing the broad systemic changes associated with direct GH administration.<o:p><\/o:p><\/p>\n<p>&nbsp;<\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"><b>Why visceral fat specifically?\u00a0 <\/b>Visceral adipocytes have the highest density of GH receptors of any fat depot in the body. They are also the most sensitive to GH-stimulated hormone-sensitive lipase activation \u2014 the enzyme responsible for mobilizing stored triglycerides. This receptor density differential is the primary reason tesamorelin-driven lipolysis is disproportionately concentrated in the visceral compartment rather than subcutaneous tissue.<o:p><\/o:p><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;2_5,3_5&#8243; use_custom_gutter=&#8221;on&#8221; make_equal=&#8221;on&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;50px||50px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/close-up-hyaluronic-acid-tratment-1-scaled.jpg&#8221; parallax=&#8221;on&#8221; border_radii=&#8221;on|12px|12px|12px|12px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height_tablet=&#8221;650px&#8221; height_phone=&#8221;420px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;What the Clinical Research Shows&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;81%&#8221; custom_margin_tablet=&#8221;15px||||false|false&#8221; custom_margin_phone=&#8221;30px||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; global_colors_info=&#8221;{}&#8221;]<ul>\n<li><span style=\"font-size: 16px;\">Tesamorelin has one of the most substantial clinical research profiles of any peptide in the GH secretagogue class. The bulk of the evidence comes from randomized, placebo-controlled Phase III trials conducted in people living with HIV (PWH) who developed lipodystrophy \u2014 characterized by excess VAT accumulation \u2014 as a complication of antiretroviral therapy.<\/span><\/li>\n<li><b style=\"font-size: 16px;\">Phase III trial findings (Falutz et al., NEJM): <\/b>In the landmark New England Journal of Medicine Phase III study of 412 patients, participants receiving tesamorelin at 2 mg daily for 26 weeks showed meaningful reductions in visceral adipose tissue on CT imaging. Subcutaneous fat and limb fat were not significantly affected \u2014 confirming the depot-selective nature of the response. Triglyceride levels and cholesterol ratios also improved significantly in the tesamorelin group.<\/li>\n<li><b style=\"font-size: 16px;\">VAT responder data: <\/b>Across two Phase III trials involving over 800 patients, the FDA defined a clinically significant VAT response as a reduction of 8% or more. In the combined trial data, 69% of tesamorelin-treated participants achieved this threshold at 26 weeks, compared to 33% of placebo-treated participants. By week 52, the responder rate in the tesamorelin group increased to 72%.<\/li>\n<\/ul>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; global_colors_info=&#8221;{}&#8221;]<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"><b>Liver fat and enzyme improvements: <\/b><o:p><\/o:p>A 2014 randomized trial published in JAMA found that <i>6 months of tesamorelin was associated with reductions in both visceral fat and liver fat<\/i> \u2014 an important secondary finding given the established link between visceral adiposity and non-alcoholic fatty liver disease (NAFLD). Separate analysis from the Phase III trials showed that VAT responders had significantly better improvements in liver enzyme markers (ALT and AST) compared to non-responders.<o:p><\/o:p><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"><b>Fat quality, not just quantity: <\/b><o:p><\/o:p>Beyond reducing fat volume, research has shown that tesamorelin also improves adipose tissue quality \u2014 measured by fat density on CT scan. Higher fat density correlates with smaller, healthier adipocytes and better adipokine secretion. This suggests tesamorelin may improve the functional profile of remaining fat tissue, not just reduce its volume.<o:p><\/o:p><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"><b>Metabolic downstream effects: <\/b><o:p><\/o:p>Participants who achieved meaningful VAT reductions with tesamorelin showed improvements in triglyceride levels, total cholesterol to HDL ratios, and adiponectin \u2014 a protein produced by fat cells that regulates glucose metabolism and fatty acid oxidation. These findings indicate that VAT reduction with tesamorelin carries systemic metabolic benefits beyond simple fat loss.<o:p><\/o:p><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;2025 Update: New Formulation and Emerging Research Areas&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;55%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; global_colors_info=&#8221;{}&#8221;]<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\">In March 2025, the FDA approved a new formulation of tesamorelin \u2014 EGRIFTA WR (F8) \u2014 which allows weekly reconstitution rather than daily, significantly reducing the injection burden for research subjects and improving long-term adherence. The new formulation delivers less than half the injection volume of its predecessor while maintaining bioequivalence.<\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"><o:p><\/o:p>Beyond its established VAT reduction profile, researchers are beginning to explore tesamorelin\u2019s effects in two emerging areas: neurocognitive function and integrase inhibitor (INSTI)-associated weight gain in HIV. Early data presented at the 2023 Conference on Retroviruses and Opportunistic Infections showed that in INSTI-treated patients, tesamorelin produced an 8.3% reduction in VAT versus a 10.8% increase in the placebo group \u2014 alongside a 31% relative reduction in hepatic fat fraction. These findings expand the potential research utility of tesamorelin beyond its original lipodystrophy indication.<o:p><\/o:p><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/retarttitude-blog-image.webp&#8221; parallax=&#8221;on&#8221; min_height=&#8221;300px&#8221; custom_margin=&#8221;25px||||false|false&#8221; border_radii=&#8221;on|8px|8px|8px|8px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243; custom_margin=&#8221;38px|||||&#8221;]<p><!-- ENHANCED DARK THEME WITH BORDERS AND BLENDED HEADING --><\/p>\n<div class=\"tesamorelin-enhanced-wrapper\">\n<h2><strong><span style=\"color: #ffffff;\">Tesamorelin vs Other GH Research Peptides<\/span><\/strong><\/h2>\n<p>Tesamorelin is one of several GHRH-related peptides used in growth hormone research. Understanding where it sits relative to compounds like CJC-1295, Ipamorelin, and Sermorelin helps researchers choose the right tool for the specific question being studied.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Peptide<\/th>\n<th>Mechanism<\/th>\n<th>Half-Life<\/th>\n<th>VAT Evidence<\/th>\n<th>Best For<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Tesamorelin<\/td>\n<td>GHRH receptor agonist (full 44-AA sequence)<\/td>\n<td>~30 min<\/td>\n<td>Phase III RCT \u2014 strongest clinical evidence in class<\/td>\n<td>Visceral fat &amp; metabolic research<\/td>\n<\/tr>\n<tr>\n<td>CJC-1295 DAC<\/td>\n<td>GHRH analog, albumin-bound<\/td>\n<td>6\u20138 days<\/td>\n<td>Preclinical only; no VAT-specific RCT data<\/td>\n<td>Sustained GH elevation; long-duration protocols<\/td>\n<\/tr>\n<tr>\n<td>Ipamorelin<\/td>\n<td>Ghrelin receptor agonist (GHRP)<\/td>\n<td>~2 hrs<\/td>\n<td>Modest, variable; not depot-specific<\/td>\n<td>Selective GH pulse; anti-aging &amp; recovery<\/td>\n<\/tr>\n<tr>\n<td>Sermorelin<\/td>\n<td>GHRH analog (1\u201329 fragment)<\/td>\n<td>~10\u201320 min<\/td>\n<td>Limited; primarily diagnostic use<\/td>\n<td>Pituitary function assessment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"highlight-box\"><strong>The key differentiator for tesamorelin is the depth of its clinical evidence base.<\/strong> It is the only GHRH analog with Phase III randomized controlled trial data specifically demonstrating visceral fat reduction \u2014 making it the most validated tool available for researchers designing studies with VAT as a primary endpoint.<\/div>\n<p>CJC-1295 with DAC offers a pharmacokinetic advantage for long-duration protocols where weekly dosing is preferred, but its effects on visceral fat specifically have not been validated in controlled human trials. Ipamorelin operates through a separate receptor pathway (ghrelin receptor rather than GHRH receptor) and produces sharper, shorter GH pulses \u2014 making it complementary to tesamorelin rather than directly comparable. Some research protocols have explored combining tesamorelin with Ipamorelin to leverage both the sustained GHRH stimulation and the pulse amplification of GHRP signaling.<\/p>\n<\/div>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_5,2_5&#8243; use_custom_gutter=&#8221;on&#8221; make_equal=&#8221;on&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;50px||50px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Key Considerations for Researchers&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;&#8211;et_global_body_font|700|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;28px&#8221; width=&#8221;81%&#8221; custom_margin_tablet=&#8221;15px||||false|false&#8221; custom_margin_phone=&#8221;30px||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<ul>\n<li>\n<p class=\"MsoListParagraph\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo1; margin: 0cm 0cm 5.0pt 36.0pt;\"><!-- [if !supportLists]-->\u2022<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0 \u00a0 \u00a0 \u00a0<\/span><!--[endif]--><b>Depot selectivity is the defining research advantage. <\/b>Tesamorelin\u2019s effects are concentrated in visceral fat, not subcutaneous fat or total body weight. Study designs should account for this by using CT-based VAT measurement as the primary body composition endpoint rather than BMI or total weight.<o:p><\/o:p><\/p>\n<p class=\"MsoListParagraph\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo1; margin: 0cm 0cm 5.0pt 36.0pt;\"><!-- [if !supportLists]-->\u2022<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><!--[endif]--><b>IGF-1 monitoring is important in longer protocols. <\/b>Tesamorelin elevates IGF-1 by approximately 80% in clinical trials. Periodic monitoring is a standard component of study design to ensure levels remain within age-appropriate reference ranges.<o:p><\/o:p><\/p>\n<p class=\"MsoListParagraph\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo1; margin: 0cm 0cm 5.0pt 36.0pt;\"><!-- [if !supportLists]-->\u2022<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><!--[endif]--><b>Effects may partially persist after discontinuation. <\/b>Research has shown that some of the metabolic benefits observed with tesamorelin persist even after the drug is stopped, though VAT tends to gradually return toward baseline. This has implications for study washout design.<o:p><\/o:p><\/p>\n<p class=\"MsoListParagraph\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo1; margin: 0cm 0cm 5.0pt 36.0pt;\"><!-- [if !supportLists]-->\u2022<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><!--[endif]--><b>Glucose metabolism warrants attention. <\/b>Mild elevations in fasting glucose and insulin have been observed in some trial participants, consistent with the known effects of GH on insulin sensitivity. Studies examining tesamorelin in metabolically compromised populations should include glycemic endpoints.<o:p><\/o:p><\/p>\n<p class=\"MsoListParagraph\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo1; margin: 0cm 0cm 5.0pt 36.0pt;\"><!-- [if !supportLists]-->\u2022<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><!--[endif]--><b>Purity and COA are non-negotiable for reproducibility. <\/b>Given tesamorelin\u2019s 44-amino-acid sequence and lipophilic modification, synthesis quality directly affects receptor binding and downstream GH response. Research-grade purity with independent HPLC and mass spectrometry verification is essential for consistent outcomes.<o:p><\/o:p><\/p>\n<\/li>\n<\/ul>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/retatritude-blog-img.webp&#8221; border_radii=&#8221;on|12px|12px|12px|12px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider show_divider=&#8221;off&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; height_tablet=&#8221;650px&#8221; height_phone=&#8221;420px&#8221; height_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||0px||false|false&#8221; custom_padding_tablet=&#8221;||80px||false|false&#8221; custom_padding_phone=&#8221;||80px||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;24px&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<p><!-- SUMMARY SECTION - DARK THEME --><\/p>\n<p>&nbsp;<\/p>\n<div class=\"summary-section-wrapper\">\n<div class=\"summary-header\">\n<h2><strong><span style=\"color: #ffffff;\">Summary<\/span><\/strong><\/h2>\n<\/div>\n<div class=\"summary-content\">\n<p>Tesamorelin stands out in the GH secretagogue research space for a simple reason: it has the data. Across multiple Phase III randomized controlled trials involving hundreds of participants, it has consistently demonstrated selective visceral fat reduction, improvements in liver fat, and downstream metabolic benefits \u2014 without meaningfully altering subcutaneous fat or overall body weight.<\/p>\n<p>For researchers studying visceral adiposity, the GH\/IGF-1 axis, metabolic syndrome, or the comparative pharmacology of growth hormone peptides, tesamorelin provides the most clinically validated foundation available in the class. Its pituitary-mediated, physiologic mechanism makes it a uniquely controlled research tool \u2014 one that produces meaningful, measurable effects in the specific fat depot most closely linked to cardiometabolic risk.<\/p>\n<div class=\"disclaimer-box\">\n<p>For laboratory research use only. All compounds sold by 99PurityPeptides are intended exclusively for in vitro and analytical research. Not for human or veterinary use.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<div class=\"product-cta-box\">\n<table class=\"MsoNormalTable\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"624\" style=\"width: 1428px; border: initial none initial;\" height=\"70\">\n<tbody>\n<tr>\n<td width=\"624\" valign=\"top\" style=\"width: 468pt; border-width: 1pt; border-right-style: solid; border-bottom-style: solid; border-left-style: solid; border-color: #cccccc; border-image: initial; background: #f9fafb; padding: 8pt 10pt;\">\n<p class=\"MsoNormal\"><i><span style=\"font-size: 10.0pt; color: #374151;\">For laboratory research use only. All compounds sold by 99PurityPeptides are intended exclusively for in vitro and analytical research. Not for human or veterinary use.<\/span><\/i><o:p><\/o:p><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"MsoNormal\" style=\"margin-bottom: 5.0pt;\"><o:p>\u00a0<\/o:p><\/p>\n<table class=\"MsoNormalTable\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"624\" style=\"width: 1429px; border: initial none initial;\" height=\"72\">\n<tbody>\n<tr>\n<td width=\"624\" valign=\"top\" style=\"width: 468pt; border-width: 1pt; border-right-style: solid; border-bottom-style: solid; border-left-style: solid; border-color: #cccccc; border-image: initial; background: #1e3a5f; padding: 8pt 10pt;\">\n<p class=\"MsoNormal\" style=\"margin-bottom: 5.0pt;\"><a href=\"https:\/\/99puritypeptides.com\/shop\/\"><b><span style=\"font-size: 12.0pt; color: white;\">\u2192 Shop 99%+ Purity Tesamorelin \u2014 COA Verified, USA Shipped<\/span><\/b><\/a><o:p><\/o:p><\/p>\n<p class=\"MsoNormal\"><span style=\"font-size: 10.0pt; color: #cbd5e1;\">HPLC and mass spectrometry verified. Certificate of Analysis included with every order. Purity guarantee: full refund if any product does not meet stated label claims.<\/span><o:p><\/o:p><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|tablet&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#0a0202&#8243; background_enable_image=&#8221;off&#8221; background_position=&#8221;center_right&#8221; custom_padding=&#8221;||||true|false&#8221; custom_padding_tablet=&#8221;||||false|false&#8221; custom_padding_phone=&#8221;||||true|false&#8221; custom_css_free_form=&#8221;@media (max-width: 1024px) and (min-width: 981px){||  selector {||    padding: 60px 0px 70px !important; ||}||}&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Questions&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Montserrat|700|||||||&#8221; title_text_align=&#8221;center&#8221; title_text_color=&#8221;#ffffff&#8221; title_font_size=&#8221;32px&#8221; title_line_height=&#8221;42px&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#fafafa&#8221; text_line_height=&#8221;26px&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;]<p><span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjI2NDgyODQ3OSwiZGF0YVR5cGUiOiJzY2VuZSJ9Cg==(\/figmeta)--&gt;\"><\/span><span data-buffer=\"&lt;!--(figma)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(\/figma)--&gt;\"><\/span><span>Common questions about research peptides, ordering, and lab standards<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=&#8221;on|tablet&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; width=&#8221;60%&#8221; width_tablet=&#8221;90%&#8221; width_phone=&#8221;90%&#8221; width_last_edited=&#8221;on|tablet&#8221; custom_margin=&#8221;30px||||false|false&#8221; custom_margin_tablet=&#8221;20px||||false|false&#8221; custom_margin_phone=&#8221;20px||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding_tablet=&#8221;0px||||false|false&#8221; custom_padding_phone=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_accordion toggle_icon=&#8221;&#x4c;||divi||400&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; border_radii=&#8221;on|8px|8px|8px|8px&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_accordion_item title=&#8221;How does tesamorelin reduce visceral fat?&#8221; open=&#8221;on&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Tesamorelin stimulates the pituitary gland to release growth hormone (GH), which elevates IGF-1 levels. Visceral adipocytes have the highest density of GH receptors in the body, making them uniquely sensitive to GH-stimulated lipolysis. This receptor density differential causes tesamorelin to selectively mobilize visceral fat while leaving subcutaneous fat largely unaffected.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;What does the clinical research show about tesamorelin and visceral fat? &#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Phase III clinical trials published in the New England Journal of Medicine showed that 69% of tesamorelin-treated participants achieved clinically significant visceral fat reduction (8% or more) at 26 weeks, compared to 33% on placebo. By week 52, the responder rate increased to 72%. Studies involved over 800 participants and used CT imaging to measure visceral adipose tissue changes.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;What cancer types has retatrutide been studied in?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<p><span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Preclinical retatrutide cancer research has focused on pancreatic ductal adenocarcinoma, lung adenocarcinoma, and triple-negative breast cancer (TNBC). The Marathe et al. study (2025) examined pancreatic and lung cancer models, while the Cui et al. study (2025) investigated TNBC, specifically looking at chemotherapy resistance mechanisms.<\/p>[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;Is retatrutide approved for cancer treatment?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<p><span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>No. Retatrutide is currently in Phase 3 clinical trials for obesity and metabolic conditions, not cancer treatment. All cancer-related findings are from preclinical mouse studies only. Retatrutide is not approved for human use in any oncological application and is available only as a research chemical for laboratory studies.<\/p>[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;Why is retatrutide being studied in cancer research?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<p><span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Researchers are studying retatrutide because obesity creates metabolic conditions that support tumor growth\u2014including chronic inflammation, elevated insulin, and immunosuppression. As a triple-receptor agonist (GLP-1, GIP, and glucagon), retatrutide alters the metabolic environment more comprehensively than single-agonist drugs, making it valuable for studying how metabolic changes affect cancer cell behavior and the tumor microenvironment.<\/p>[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;How does tesamorelin compare to CJC-1295 for visceral fat research?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Tesamorelin has Phase III randomized controlled trial data specifically demonstrating visceral fat reduction, making it the most clinically validated GHRH analog in this area. CJC-1295 DAC offers a longer half-life (6-8 days vs 30 minutes) and sustained GH elevation, but has no VAT-specific RCT data. CJC-1295 is better suited for long-duration protocols requiring weekly dosing, while tesamorelin is the gold standard for visceral fat research.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;What is the standard tesamorelin dosage in clinical trials?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Clinical trials used 2 mg of tesamorelin administered daily via subcutaneous injection. A new FDA-approved formulation (EGRIFTA WR\/F8) released in March 2025 allows weekly reconstitution rather than daily, reducing injection burden while maintaining bioequivalence with less than half the injection volume.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;Does tesamorelin affect liver fat?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Yes. A 2014 JAMA study found that 6 months of tesamorelin reduced both visceral fat and liver fat. Additionally, Phase III trial analysis showed that participants who achieved meaningful VAT reductions had significantly better improvements in liver enzyme markers (ALT and AST) compared to non-responders, suggesting benefits for non-alcoholic fatty liver disease (NAFLD).[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;What are the metabolic benefits of tesamorelin beyond fat reduction?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Clinical research shows tesamorelin improves multiple metabolic markers including triglyceride levels, total cholesterol to HDL ratios, and adiponectin (which regulates glucose metabolism). It also improves adipose tissue quality measured by fat density on CT scans, indicating healthier adipocytes and better adipokine secretion. These systemic benefits extend beyond simple fat volume reduction.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;How long do tesamorelin&#8217;s effects last after discontinuation?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Research indicates that some metabolic benefits persist after tesamorelin is stopped, though visceral adipose tissue tends to gradually return toward baseline. This has important implications for study washout design and suggests the compound may produce lasting metabolic improvements even with discontinuation.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;What is the difference between tesamorelin and Ipamorelin?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Tesamorelin is a GHRH receptor agonist that stimulates sustained growth hormone release through the pituitary, while Ipamorelin is a ghrelin receptor agonist (GHRP) that produces sharper, shorter GH pulses. Tesamorelin has strong Phase III evidence for visceral fat reduction, while Ipamorelin&#8217;s VAT effects are modest and not depot-specific. Some protocols combine both to leverage GHRH stimulation and GHRP pulse amplification.[\/et_pb_accordion_item][et_pb_accordion_item title=&#8221;What should researchers monitor when using tesamorelin in studies?&#8221; open_toggle_text_color=&#8221;#fafafa&#8221; open_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; closed_toggle_text_color=&#8221;#fafafa&#8221; closed_toggle_background_color=&#8221;RGBA(255,255,255,0)&#8221; icon_color=&#8221;#fafafa&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; body_font=&#8221;Montserrat||||||||&#8221; body_text_color=&#8221;#fafafa&#8221; body_font_size=&#8221;14px&#8221; body_line_height=&#8221;24px&#8221; custom_padding=&#8221;25px||25px||true|false&#8221; global_colors_info=&#8221;{}&#8221; toggle_text_color=&#8221;#fafafa&#8221; toggle_level=&#8221;h3&#8243; toggle_font=&#8221;Montserrat|700|||||||&#8221; toggle_font_size=&#8221;18px&#8221; toggle_line_height=&#8221;100%&#8221; closed_toggle_font=&#8221;Montserrat|700|||||||&#8221; closed_toggle_font_size=&#8221;18px&#8221; closed_toggle_line_height=&#8221;100%&#8221; open=&#8221;off&#8221;]<span data-metadata=\"&lt;!--(figmeta)eyJmaWxlS2V5IjoieTVpb1k4OHM4dWNnQ1JjNUQ2R01VViIsInBhc3RlSUQiOjIwNjY0MjAzMDUsImRhdGFUeXBlIjoic2NlbmUifQo=(\/figmeta)--&gt;\"><\/span>Key monitoring points include: \n(1) CT-based VAT measurement as the primary endpoint rather than BMI, \n(2) IGF-1 levels, which typically rise approximately 80% and should remain within age-appropriate ranges, \n(3) glucose metabolism markers including fasting glucose and insulin, as mild elevations have been observed, and \n(4) compound purity via HPLC and mass spectrometry verification for reproducible results.[\/et_pb_accordion_item][\/et_pb_accordion][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;40px||||false|false&#8221; custom_padding=&#8221;||40px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Still have questions?&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; title_font=&#8221;Montserrat|700|||||||&#8221; title_text_align=&#8221;center&#8221; title_text_color=&#8221;#ffffff&#8221; title_font_size=&#8221;32px&#8221; title_line_height=&#8221;42px&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#fafafa&#8221; text_line_height=&#8221;26px&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||0px||true|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;]Reach out to our team anytime[\/et_pb_text][et_pb_button button_url=&#8221;\/contact-us&#8221; button_text=&#8221;contact&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;14px&#8221; button_text_color=&#8221;#ffffff&#8221; button_bg_color=&#8221;#1e5d68&#8243; button_border_radius=&#8221;8px&#8221; button_font=&#8221;&#8211;et_global_heading_font|600||on|||||&#8221; button_use_icon=&#8221;off&#8221; custom_margin=&#8221;10px||||false|false&#8221; custom_padding=&#8221;16px||16px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"<p>Not all fat is created equal. While subcutaneous fat \u2014 the kind you can pinch beneath the skin \u2014 is largely cosmetic, visceral fat is a different matter entirely. Stored deep in the abdominal cavity and wrapped around the organs, visceral adipose tissue (VAT) is metabolically active, pro-inflammatory, and directly associated with cardiovascular disease, insulin [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3388,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"2880","footnotes":""},"categories":[1],"tags":[],"class_list":["post-3386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tirzepatide"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tesamorelin Visceral Fat Research: Clinical Data 2025<\/title>\n<meta name=\"description\" content=\"Phase III trials show tesamorelin reduces visceral fat by 69% in 26 weeks. Learn how this GHRH analog targets VAT to CJC-1295.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-research\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesamorelin Visceral Fat Research: Clinical Data 2025\" \/>\n<meta property=\"og:description\" content=\"Phase III trials show tesamorelin reduces visceral fat by 69% in 26 weeks. Learn how this GHRH analog targets VAT to CJC-1295.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-research\/\" \/>\n<meta property=\"og:site_name\" content=\"99 Purity Peptides\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T20:06:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T21:37:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/Tesamorelin-and-Visceral-Fat-What-the-Research-Shows-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tech-Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tech-Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutos\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tesamorelin Visceral Fat Research: Clinical Data 2025","description":"Phase III trials show tesamorelin reduces visceral fat by 69% in 26 weeks. Learn how this GHRH analog targets VAT to CJC-1295.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-research\/","og_locale":"es_MX","og_type":"article","og_title":"Tesamorelin Visceral Fat Research: Clinical Data 2025","og_description":"Phase III trials show tesamorelin reduces visceral fat by 69% in 26 weeks. Learn how this GHRH analog targets VAT to CJC-1295.","og_url":"https:\/\/99puritypeptides.com\/es\/tesamorelin-visceral-fat-research\/","og_site_name":"99 Purity Peptides","article_published_time":"2026-03-31T20:06:05+00:00","article_modified_time":"2026-03-31T21:37:24+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/Tesamorelin-and-Visceral-Fat-What-the-Research-Shows-scaled.jpg","type":"image\/jpeg"}],"author":"Tech-Admin","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Tech-Admin","Tiempo de lectura":"10 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#article","isPartOf":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/"},"author":{"name":"Tech-Admin","@id":"https:\/\/99puritypeptides.com\/#\/schema\/person\/e55552079f2f37ec910151ea4b2951dd"},"headline":"Tesamorelin and Visceral Fat: What the Research Shows","datePublished":"2026-03-31T20:06:05+00:00","dateModified":"2026-03-31T21:37:24+00:00","mainEntityOfPage":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/"},"wordCount":4943,"publisher":{"@id":"https:\/\/99puritypeptides.com\/#organization"},"image":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#primaryimage"},"thumbnailUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/Tesamorelin-and-Visceral-Fat-What-the-Research-Shows-scaled.jpg","articleSection":["Tirzepatide"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/","url":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/","name":"Tesamorelin Visceral Fat Research: Clinical Data 2025","isPartOf":{"@id":"https:\/\/99puritypeptides.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#primaryimage"},"image":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#primaryimage"},"thumbnailUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/Tesamorelin-and-Visceral-Fat-What-the-Research-Shows-scaled.jpg","datePublished":"2026-03-31T20:06:05+00:00","dateModified":"2026-03-31T21:37:24+00:00","description":"Phase III trials show tesamorelin reduces visceral fat by 69% in 26 weeks. Learn how this GHRH analog targets VAT to CJC-1295.","breadcrumb":{"@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#primaryimage","url":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/Tesamorelin-and-Visceral-Fat-What-the-Research-Shows-scaled.jpg","contentUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2026\/03\/Tesamorelin-and-Visceral-Fat-What-the-Research-Shows-scaled.jpg","width":2560,"height":1707,"caption":"Tesamorelin and Visceral Fat What the Research Shows"},{"@type":"BreadcrumbList","@id":"https:\/\/99puritypeptides.com\/tesamorelin-visceral-fat-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/99puritypeptides.com\/"},{"@type":"ListItem","position":2,"name":"Tesamorelin and Visceral Fat: What the Research Shows"}]},{"@type":"WebSite","@id":"https:\/\/99puritypeptides.com\/#website","url":"https:\/\/99puritypeptides.com\/","name":"99 Purity Peptides","description":"","publisher":{"@id":"https:\/\/99puritypeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/99puritypeptides.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/99puritypeptides.com\/#organization","name":"99 Purity Peptides","url":"https:\/\/99puritypeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/99puritypeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2025\/12\/99-Purity-Peptides-logo.png","contentUrl":"https:\/\/99puritypeptides.com\/wp-content\/uploads\/2025\/12\/99-Purity-Peptides-logo.png","width":239,"height":100,"caption":"99 Purity Peptides"},"image":{"@id":"https:\/\/99puritypeptides.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/99puritypeptides.com\/#\/schema\/person\/e55552079f2f37ec910151ea4b2951dd","name":"Tech-Admin","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/40f1be3f1f5d04abecbd756bd94581cbf8ad889cae584be7a6fd1e9f8eacdd77?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/40f1be3f1f5d04abecbd756bd94581cbf8ad889cae584be7a6fd1e9f8eacdd77?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/40f1be3f1f5d04abecbd756bd94581cbf8ad889cae584be7a6fd1e9f8eacdd77?s=96&d=mm&r=g","caption":"Tech-Admin"},"sameAs":["https:\/\/99puritypeptides.com"]}]}},"_links":{"self":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts\/3386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/comments?post=3386"}],"version-history":[{"count":0,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/posts\/3386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/media\/3388"}],"wp:attachment":[{"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/media?parent=3386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/categories?post=3386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/99puritypeptides.com\/es\/wp-json\/wp\/v2\/tags?post=3386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}